List of Excipients in Branded Drug ERTACZO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	ETHYLENE GLYCOL
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	GLYCERYL ISOSTEARATE
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	GLYCOL STEARATE
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	LIGHT MINERAL OIL
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	METHYLPARABEN
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	PEG-32 STEARATE
Bausch Health US LLC	ERTACZO	sertaconazole nitrate	0187-5115	PEG-6 STEARATE

Generic Drugs Containing ERTACZO

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	ertaczo	21695-454	ETHYLENE GLYCOL
Rebel Distributors Corp	ertaczo	21695-454	LIGHT MINERAL OIL
Rebel Distributors Corp	ertaczo	21695-454	METHYLPARABEN
Rebel Distributors Corp	ertaczo	21695-454	POLYETHYLENE GLYCOL
Rebel Distributors Corp	ertaczo	21695-454	SORBIC ACID
Rebel Distributors Corp	ertaczo	21695-454	WATER

What are the Most Frequently-Used Excipients in ERTACZO?

# Of NDCs	Excipient
1	ETHYLENE GLYCOL
1	LIGHT MINERAL OIL
1	METHYLPARABEN
1	POLYETHYLENE GLYCOL
1	SORBIC ACID
1	WATER

ERTACZO Excipient Strategy and Commercial Opportunities for Sertaconazole Nitrate 2% Cream

Last updated: August 22, 2026

ERTACZO is a prescription topical antifungal containing sertaconazole nitrate 2% in a cream vehicle. Its commercial opportunity is concentrated in formulation differentiation, generic substitution, alternative delivery systems, and lifecycle products for superficial dermatophytosis. The current cream relies on a conventional oil-in-water emulsion with fatty alcohols, glyceryl monostearate, isopropyl myristate, polysorbate 60, organic-acid preservatives, and purified water. [1]

The strongest development opportunities are improved spreadability, reduced residue, lower irritation potential, preservative optimization, once-daily adherence, and delivery formats better suited to interdigital tinea pedis and other localized fungal infections.

What is ERTACZO and which excipients does it contain?

ERTACZO contains sertaconazole nitrate 2% and is indicated for the topical treatment of interdigital tinea pedis in patients aged 12 years and older. The labeled regimen is once daily for two weeks. [1]

ERTACZO composition

Component	Role in formulation	Commercial relevance
Sertaconazole nitrate 2%	Active antifungal ingredient	Controls antifungal efficacy, crystallization, and particle-size requirements
Benzoic acid	Preservative and pH-modifying organic acid	May contribute to preservation and local tolerability
Sorbic acid	Preservative	Supports microbial protection in the aqueous cream
Cetyl alcohol	Structuring agent and emollient	Builds viscosity and cream body
Stearyl alcohol	Structuring agent and emollient	Supports consistency and skin feel
Glyceryl monostearate	Emulsifier and consistency agent	Stabilizes the semisolid vehicle
Isopropyl myristate	Emollient and penetration-enhancing excipient	Improves spreadability and skin feel
Polysorbate 60	Nonionic surfactant	Supports oil-in-water emulsion stability
Purified water	Continuous aqueous phase	Determines hydration, rheology, and preservation burden

The formulation is a conventional semisolid cream rather than a foam, gel, spray, powder, or film-forming system. That creates room for differentiated products, but any reformulation must preserve sertaconazole solubilization, uniformity, microbial quality, physical stability, and clinical performance.

How does the ERTACZO cream vehicle influence product performance?

The excipient system performs four commercial functions: it distributes sertaconazole across the skin, controls application feel, supports product stability, and enables a two-week once-daily regimen.

Emulsion structure

Cetyl alcohol, stearyl alcohol, glyceryl monostearate, and polysorbate 60 form the structural framework of the cream. These materials affect viscosity, phase stability, rub-in time, residue, and package compatibility.

An emulsion with excessive fatty alcohol or glyceryl monostearate can feel waxy and leave visible residue. A lower-structure system may improve spreadability but increase phase-separation risk, active crystallization, or leakage from tubes. The optimal target is a low-residue cream that remains physically stable across temperature excursions.

Skin feel and adherence

Isopropyl myristate provides an emollient, low-viscosity feel and may improve distribution across the interdigital spaces. It can also increase the risk of irritation or follicular effects in susceptible users. Formulators evaluating substitutes should compare caprylic/capric triglyceride, diisopropyl adipate, C12-15 alkyl benzoate, and selected silicone emollients.

The commercial objective is not maximum penetration alone. It is reliable patient use once daily for the full treatment course.

Preservative system

Benzoic acid and sorbic acid are pH-dependent preservatives. Their activity is strongest in an acidic environment, making pH control critical. Reformulation can target lower preservative load, but the product must pass antimicrobial effectiveness testing and maintain preservation through the labeled shelf life. [2]

Preservative reduction may create a marketable "sensitive skin" positioning, but it cannot be treated as a cosmetic claim without evaluating the applicable drug-labeling and advertising requirements.

Active-ingredient presentation

Sertaconazole nitrate is a salt with formulation behavior that must be assessed in the selected vehicle. Development work should establish whether the drug is fully dissolved, partially suspended, or present in a mixed state. Changes in solvent polarity, surfactant concentration, pH, or emollient composition can alter:

• Drug crystallization
• Particle-size distribution
• Dose uniformity
• Release rate
• Skin permeation
• Long-term stability
• Comparative clinical performance

A visually attractive cream with faster release may not be therapeutically equivalent to the reference product.

What excipient strategies could improve ERTACZO?

Four formulation strategies have the clearest commercial logic: optimized cream, low-residue gel-cream, film-forming system, and alternative delivery format.

Strategy 1: Optimize the conventional cream

This is the lowest regulatory and manufacturing-risk option. The developer would retain the general semisolid architecture while modifying the oil phase, emulsifier ratio, rheology, or preservative system.

Potential objectives include:

• Faster rub-in
• Lower waxiness
• Less visible residue between toes
• Improved wash resistance
• Better cold-temperature stability
• Reduced preservative concentration
• Improved compatibility with laminate or high-density polyethylene tubes

Candidate excipient substitutions include C12-15 alkyl benzoate, caprylic/capric triglyceride, dimethicone, glyceryl behenate, poloxamers, and acrylate-based rheology modifiers. Each substitution changes the product's microstructure and requires comparative release and stability testing.

This approach is commercially attractive for a generic or authorized-generic product because the formulation can remain close to the reference product while targeting manufacturing efficiency and patient preference.

Strategy 2: Develop a low-residue gel-cream

A gel-cream could reduce the greasy perception associated with fatty alcohol-based creams. Carbomer, acrylate crosspolymers, hydroxyethylcellulose, or poloxamer systems could be evaluated as rheology modifiers.

The principal technical risk is sertaconazole nitrate solubility and uniformity. A gel vehicle may require co-solvents or surfactants that increase irritation. It may also dry rapidly and form a film that affects drug release.

The strongest use case is interdigital tinea pedis, where patients may prefer a product that dries quickly and does not create a moist or occlusive feel between the toes.

Strategy 3: Use a film-forming vehicle

A film-forming system could provide longer residence on the skin and reduce application frequency or transfer to socks. Candidate polymers include polyvinylpyrrolidone derivatives, acrylate copolymers, cellulose derivatives, and selected polyurethane dispersions.

The commercial value would depend on demonstrating one or more of the following:

• Better retention after washing
• Reduced application frequency
• Improved adherence
• Lower transfer to clothing
• Comparable or superior mycological cure

Film-forming claims require careful clinical substantiation. A persistent film can also increase irritation, alter hydration, or cause cracking in interdigital skin.

Strategy 4: Evaluate foam, spray, or solution formats

A foam or spray can improve application to larger or difficult-to-reach areas. Such products may command higher pricing and offer differentiated packaging.

The formulation risks include:

• Reduced dose precision
• Propellant compatibility
• Flammability controls
• Container closure leakage
• Evaporation-driven concentration changes
• Skin-cooling or irritation effects
• Uneven application through hair or fissured skin

A spray may be more commercially relevant for athlete's foot affecting broad plantar areas. A foam could be useful when patients avoid creams because of greasiness.

What commercial opportunities exist for ERTACZO reformulation?

The opportunity set is strongest where formulation changes solve a recognized use problem rather than merely changing inactive ingredients.

Opportunity	Product concept	Commercial rationale	Development burden
Generic cream	Close formulation to ERTACZO	Lower substitution risk and established dosage form	Moderate
Premium cream	Lower-residue, faster-rub-in cream	Supports branded or authorized-generic positioning	Moderate to high
Gel-cream	Quick-drying semisolid	Targets adherence and patient preference	High
Film-forming solution	Longer skin residence	Could support reduced transfer and differentiated dosing	High
Foam	Rapid application with low residue	Expands convenience positioning	High
Spray	Broad-area application	Useful for plantar or multifocal disease	High
Preservative-optimized cream	Lower organic-acid load or alternative preservation	Addresses tolerability and formulation positioning	Moderate
Combination product	Sertaconazole with another active	Broadens clinical positioning but increases regulatory complexity	Very high

A conventional generic cream is likely to face the most direct price competition. A differentiated vehicle can support higher gross margins, but it must demonstrate enough clinical or adherence value to justify regulatory and manufacturing costs.

How does ERTACZO compare with competing topical antifungals?

ERTACZO competes with topical products containing terbinafine, butenafine, clotrimazole, miconazole, ciclopirox, and econazole. Competitive differentiation depends on treatment duration, dosing frequency, formulation feel, spectrum, tolerability, and retail availability.

Product class	Typical commercial positioning	Excipient opportunity
Sertaconazole 2% cream	Prescription topical antifungal; once-daily, two-week course for interdigital tinea pedis	Improve residue, drying time, and packaging
Terbinafine products	Strong OTC presence and short-course positioning	Compete through vehicle feel and prescription differentiation
Azole creams	Broad category with multiple OTC and Rx products	Differentiate with adherence, tolerability, or delivery format
Ciclopirox products	Prescription antifungal with multiple dosage forms	Compete through application convenience
Butenafine products	OTC topical antifungal	Compete through prescription support and formulation quality

The largest commercial constraint is not only formulation performance. It is channel access. OTC products have broader consumer reach, while ERTACZO remains a prescription product under its FDA-approved labeling. [1]

When does ERTACZO lose exclusivity and what is the generic-entry risk?

ERTACZO's market exclusivity depends on the remaining term of any applicable patents, regulatory exclusivity, and the status of approved abbreviated applications. FDA approval alone does not establish current market exclusivity.

For a topical cream, generic-entry risk can arise through an ANDA referencing the listed drug. A generic applicant may seek approval by demonstrating pharmaceutical equivalence and bioequivalence using FDA-accepted methods. For complex topical products, in vitro release testing, comparative permeation data, characterization of the reference product, and formulation sameness can become important development issues. FDA's product-specific guidance and topical-product bioequivalence framework determine the evidentiary burden. [3, 4]

Paragraph IV risk

If an unexpired patent is listed for ERTACZO in the FDA Orange Book, a generic applicant could submit a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. The patent holder could then bring an infringement action within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework. [5]

For a topical product, the commercial impact of a Paragraph IV filing depends on:

• Whether the patent covers the drug substance, formulation, or method of use
• Whether the patent is listed in the Orange Book
• Whether the generic uses the same inactive ingredients
• Whether a noninfringing formulation can be developed
• Whether litigation results in an early-entry settlement

No current litigation or settlement should be inferred solely from the existence of a branded product or a historical patent family.

What patents protect ERTACZO and its excipient strategy?

Patent protection for ERTACZO may involve separate categories:

1. Sertaconazole composition-of-matter patents.
2. Formulation patents covering cream composition, concentration, pH, particle size, or excipient ratios.
3. Method-of-use patents covering treatment of fungal infections.
4. Manufacturing patents covering drug dispersion, homogenization, or crystallization control.
5. Packaging patents covering container systems or delivery devices.

Excipient substitution can avoid a narrow formulation claim, but it may also create a new patentable formulation if the resulting system demonstrates a distinct stability, release, permeation, or adherence profile.

The strongest formulation patents generally claim measurable technical parameters rather than a broad list of common excipients. Examples include defined drug-excipient ratios, a specified pH range, a particle-size distribution, a release profile, or improved stability under accelerated conditions.

For commercial diligence, the relevant sources are the FDA Orange Book, USPTO Patent Center, WIPO PATENTSCOPE, and patent litigation records. [5-8]

Is there biosimilar risk for ERTACZO?

There is no conventional biosimilar risk because ERTACZO is a small-molecule topical drug, not a biologic. Competitive entry would generally occur through an ANDA, a 505(b)(2) application, or, for certain products, an alternative regulatory route depending on the proposed dosage form and active ingredient. [3, 9]

A 505(b)(2) strategy could be relevant for a materially different foam, spray, film-forming system, or combination product. The applicant may rely in part on FDA findings for the reference product while generating additional clinical or pharmacokinetic data for the new formulation.

What FDA regulatory issues affect a reformulated ERTACZO product?

A close generic cream and a materially different delivery system face different regulatory paths.

Product concept	Likely regulatory pathway	Principal evidence
Same active, same dosage form, close formulation	ANDA	Pharmaceutical equivalence, product quality, bioequivalence
New vehicle with same active	505(b)(2) or applicable abbreviated pathway	Comparative quality, performance, and possibly clinical data
Foam or spray	505(b)(2) is a potential route	Device-container data, dose delivery, safety, efficacy
Combination product	NDA or 505(b)(2) depending on precedent	Combination rationale and clinical evidence
OTC switch	NDA supplement or other FDA-supported pathway	Self-selection, labeling, safety, efficacy, consumer-use data

The key technical package should include assay, impurities, content uniformity, rheology, particle-size distribution, polymorphic or solid-state characterization, in vitro release, microbial limits, preservative effectiveness, container closure integrity, photostability, freeze-thaw stability, and long-term stability. FDA's topical-product guidance emphasizes product quality and comparative performance because traditional systemic bioequivalence measures may not adequately capture local action. [3, 4]

How strong is the ERTACZO patent estate?

The commercial strength of the estate depends more on surviving formulation and method-of-use claims than on the historical existence of an active-ingredient patent.

Patent category	Strategic value	Risk to a follow-on product
Composition of matter	High while unexpired	Can block the active ingredient entirely
Cream formulation	Moderate to high	May require excipient redesign
Method of use	Variable	Can restrict labeled indications or dosing
Manufacturing process	Moderate	Often avoidable through process changes
Packaging or applicator	Low to moderate	Usually avoidable with alternate packaging

A formulation estate is stronger when it covers performance-defining features that are difficult to design around, such as a narrow particle-size range, defined release behavior, or a specific stability advantage. Broad claims based only on common excipients are more vulnerable to validity and design-around challenges.

What licensing and partnership opportunities exist?

The most practical licensing opportunities are likely to involve formulation technology rather than the historical ERTACZO brand itself.

Potential partners include:

• Specialty dermatology companies seeking prescription topical products
• Generic manufacturers with semisolid manufacturing capacity
• Contract development and manufacturing organizations
• Drug-delivery companies with film-forming or foam platforms
• Consumer-health companies pursuing OTC antifungal products
• Regional licensees with established dermatology sales channels

A licensing package would be more valuable if it includes a validated formulation, freedom-to-operate analysis, scalable manufacturing process, stability data, and a clear regulatory pathway. A mere excipient concept has limited transaction value until it demonstrates comparative performance and manufacturability.

What generic launch scenarios exist for ERTACZO?

Three launch scenarios are commercially relevant.

Early Paragraph IV launch

A generic applicant challenges an Orange Book patent and prevails in litigation, reaches an early-entry settlement, or obtains approval after the relevant stay and exclusivity periods expire. This scenario creates immediate price pressure on the branded cream.

Post-expiry conventional generic entry

Multiple ANDA applicants enter after patent and exclusivity barriers lapse. The product becomes primarily a cost and supply-chain competition, with limited room for premium pricing.

Differentiated follow-on entry

A manufacturer launches a gel-cream, foam, spray, or film-forming product through an appropriate regulatory route. This product may avoid direct price comparison with the reference cream but faces higher development and market-education costs.

What revenue exposure does ERTACZO create?

Publicly available labeling establishes the product's indication and formulation but does not, by itself, establish current brand revenue. Revenue exposure should be assessed through prescription volume, payer reimbursement, channel mix, competing generic availability, and the proportion of sales attributable to the ERTACZO cream versus other dermatology products.

The main revenue risks are:

• Generic cream substitution
• Payer preference for lower-cost topical antifungals
• OTC competition from terbinafine and azole products
• Limited indication breadth under the approved label
• Low treatment duration and finite refill demand
• Physician preference for familiar topical alternatives

A reformulated product can improve economics only if the vehicle produces measurable adherence, convenience, or clinical value.

Key Takeaways

• ERTACZO is a sertaconazole nitrate 2% prescription cream for interdigital tinea pedis.
• Its excipient system is a conventional oil-in-water emulsion built around fatty alcohols, glyceryl monostearate, isopropyl myristate, polysorbate 60, benzoic acid, sorbic acid, and purified water.
• The highest-probability development strategy is an optimized low-residue cream.
• Gel-cream, foam, spray, and film-forming products offer greater differentiation but carry higher regulatory and technical risk.
• Generic competition is likely to focus on cream-based ANDA products, while materially different vehicles may require a 505(b)(2) strategy.
• ERTACZO has no biosimilar risk because it is a small-molecule topical drug.
• Reformulation patents are strongest when they claim measurable technical parameters, including release, stability, particle size, or defined excipient ratios.
• Commercial value depends on solving adherence and application problems, not on excipient substitution alone.

FAQs

Can ERTACZO be reformulated as an OTC product?

A switch to OTC status would require FDA review of consumer labeling, self-selection, safety, efficacy, and use conditions. The current prescription labeling does not establish OTC eligibility.

Which excipients are most likely to improve ERTACZO spreadability?

C12-15 alkyl benzoate, caprylic/capric triglyceride, selected silicones, and lower-wax structural systems are potential candidates. Their suitability depends on sertaconazole solubility, release, irritation, and stability.

Is a preservative-free ERTACZO cream commercially feasible?

It may be feasible in a suitable package, such as a unit-dose or airless system, but microbial protection and in-use stability must be demonstrated. Removing benzoic acid and sorbic acid would materially change the formulation's preservation strategy.

Would an ERTACZO foam have better market potential than the current cream?

A foam could offer lower residue and easier application, especially for broad plantar disease. Its commercial advantage would require evidence of comparable antifungal performance and reliable dose delivery.

Can an ERTACZO generic use different inactive ingredients?

An ANDA applicant may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, safety, quality, and bioequivalence. A different excipient system can increase development complexity and may require a non-ANDA pathway.

References

1. U.S. Food and Drug Administration. (2023). ERTACZO (sertaconazole nitrate) cream, 2% prescribing information. DailyMed.

2. U.S. Pharmacopeia. (2023). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2022). Topical dermatologic drug product NDAs and ANDAs: Product quality guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

6. United States Patent and Trademark Office. (2024). Patent Center. U.S. Department of Commerce.

7. World Intellectual Property Organization. (2024). PATENTSCOPE database. WIPO.

8. U.S. Courts. (2024). Hatch-Waxman Act and pharmaceutical patent litigation resources. Administrative Office of the United States Courts.

9. U.S. Food and Drug Administration. (2024). 505(b)(2) applications. U.S. Department of Health and Human Services.